Clinical Trial Closeup

Targeted approach to pan-VEGF inhibition

A suprachoroidal formulation of axitinib, approved for renal cell carcinoma, may have potential for treating neovascular AMD.

A potential disrupter of GA progression

A post-hoc analysis shows that pegcetacoplan may disrupt the complement pathway to potentially stabilize nascent or early atrophy.

PDS with ranibizumab: It’s in the technique

A closer look at Archway results and ‘a few important details’ for the implantation procedure that drives outcomes.

Targeting a key GA factor at its source

Investigational treatment FB-LRX targets complement factor B further up the complement cascade.

Targeting a novel enzyme in GA

An investigative antibody aims to inhibit HtrA1 that contributes to progression of geographic atrophy.

Potential of KSI-301 to extend treatment

The latest results reported efficacy up to five months after the last loading dose.

Modulating macrophages to target GA

Investigational candidate aims to change macrophage behavior in management of dry age-related macular degeneration.

Wet AMD gene therapy shows promise

Phase I/IIa results of RGX-314 confirm protein uptake over months.

What’s Next for Bispecific Antibody Faricimab

With the Phase II BOULEVARD trial completed, this dual-action, single-molecule agent for DME heads into Phase III trials.

A Deeper Dive Into Abicipar Trials

Answers about vision outcomes, inflammation and where it fits in the treatment armamentarium.

Video Vault

Minimally invasive management of lenticular deposits

Akshay Thomas, MD, MS, of Tennessee Retina demonstrates his surgical technique for removing posterior intraocular lens deposits.